A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to
 assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting
 Multiple Sclerosis (RRMS) who have had a suboptimal response to an adequate course of a
 Disease-Modifying Treatment (DMT). The study will consist of a Screening period (up to 4
 weeks), an Open-label treatment period (96 weeks; with last dose administered at Week 72),
 and a Follow-up period of at least 2 years.
Inclusion Criteria:

 -  Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria

 -  Have a length of disease duration, from first symptom, of less than (<) 10 years

 -  Have received no more than two prior DMTs, and the discontinuation of the most recent
 DMT was due to lack of efficacy

 -  Suboptimal disease control while on a DMT

 -  Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening

 -  For women of childbearing potential: agreement to use an acceptable birth control
 method during the treatment period and for at least 6 months after the last dose of
 study drug

 Exclusion Criteria:

 -  Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or
 progressive relapsing multiple sclerosis (MS)

 -  Inability to complete an Magnetic Resonance Imaging (MRI) procedure

 -  Known presence of other neurological disorders

 -  Any concomitant disease that may require chronic treatment with systemic
 corticosteroids or immunosuppressants during the course of the study

 -  History or currently active primary or secondary immunodeficiency

 -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
 antibodies

 -  History of opportunistic infections

 -  History or known presence of recurrent or chronic infection

 -  History of malignancy

 -  Congestive heart failure

 -  Known active bacterial, viral, fungal, mycobacterial infection or other infection,
 excluding fungal infection of nail beds